- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Contact us
- Thank you
XVIVO Perfusion granted Breakthrough Device Designation from the FDA for the XVIVO Heart Preservation System
The Center for Devices and Radiological Health (CDRH) of the FDA has informed XVIVO that the combination product and proposed indication for use has met the criteria and have been granted designation as a Breakthrough Device. The proposed indications for use include The XVIVO Heart Preservation System (XHPS), used in conjunction with Supplemented XVIVO Heart Solution (SXHS), is indicated for the hypothermic non-ischemic perfusion of excised donor hearts for preservation prior to transplant. The device is intended to be used for all standard criteria donor hearts with the intention of transplant into a recipient aged 18 or older on a heart transplant waiting list.
The Breakthrough Devices Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The overall goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the FDA's mission to protect and promote public health.
“The ‘Breakthrough Device Designation’ granted to XVIVO offers a great opportunity to interact with the FDA and they will also provide XVIVO with a priority review and interactive communication regarding device development through to clinical trial protocols” says Dr. Magnus Nilsson, CEO of XVIVO Perfusion AB.
December 16, 2019
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, firstname.lastname@example.org
Magnus Nilsson, CEO, +46 31 788 2150, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication, through the agency of the contact person set out above, at 11:00 am CET on December 16, 2019.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.